Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.
D000450:Aldosterone / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D018849:Controlled Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000077545:Eplerenone; D005260:Female; D006801:Humans; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D011379:Prognosis; D018161:Receptors, Mineralocorticoid / Q000187:drug effects / Q000378:metabolism; D051437:Renal Insufficiency / Q000517:prevention & control*; D018570:Risk Assessment; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone